Skip to content
Search

Latest Stories

ASDA announces closure of seven in-store pharmacies

A week after LloydsPharmacy announced the closure of all its pharmacy branches in Sainsbury’s store, ASDA has also revealed the closing of seven pharmacies of its 254 in-store pharmacies.

“ASDA have announced cost cutting changes to their stores, placings hundreds of employees at risk of redundancy and thousands facing a pay cut,” said the Pharmacists Defence Association (PDA).


The association has raised concern on all pharmacists impacted those impacted by the closure of seven in-store pharmacies.

The PDA Union will support individual PDA members impacted by the decision so that they are aware of, and can exercise, their rights at work in relation to this situation.

Paul Day, PDA Union Director said, “In addition to the immediate impact on pharmacists employed at the stores marked for closure, this is a worrying further instance of reductions in access to a pharmacy for patients and we expect those who represent communities to be concerned about the loss of a key part of their local NHS service. ”

The PDA also highlights that as politicians talk about asking community pharmacy to take on more of the NHS workload, the government need to clarify what is being done to ensure the overall sector has the capacity to do so. Capacity lost in supermarkets needs to be gained on the High Street or elsewhere in the community.

“The NHS is also responsible for the funding level of the contract with community pharmacy operators, and in England under the previous Chief Pharmaceutical Officer, it chose to underfund the contract, causing predictable pressure on its viability, which is almost certain to be a factor in any corporation’s decisions to close pharmacies.”

Impact on other pharmacies

Closures can also bring consequences for those who are not at risk of redundancy. For example, if significant patient volume migrates to another pharmacy, there must be enough additional resources, staffing and physical space in that pharmacy to safely cope with the increase in business.

Many pharmacists told the PDA that they are already concerned about resource levels and so other pharmacy operators in close proximity to closing pharmacies need to be planning ahead to ensure their own pharmacies are adequately resourced for future volume.

As in the case of any job loss, the PDA Union will be doing all it can for those members impacted by this decision.

PDA Union will be expecting pharmacists to receive adequate redundancy compensation and fair treatment as they try and seek alternative employment during any notice period.

Paul Day continued, “Those pharmacists who are PDA members can contact our service centre for advice in due course and in the meantime should ensure they read communications from the PDA.”

“However, a pharmacy closure would lead to the end of a pharmacist’s employment if there are no suitable alternatives available with the employer.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less